BARRECA, MARCO
BARRECA, MARCO
DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE
Deciphering the Tumor Microenvironment Composition Using Bulk Transcriptomics: A Guide to Recent Advances and Open Challenges
2026 Ouzounis, S; Zojaji, D; García-Mulero, S; Barreca, M; Gandellini, P; Katsila, T; Sanz-Pamplona, R; Callari, M
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
2025 Callari, M; Dugo, M; Barreca, M; Győrffy, B; Galbardi, B; Vigano, L; Locatelli, A; Dall'Ara, C; Ferrarini, M; Bisagni, G; Colleoni, M; Mansutti, M; Zamagni, C; Del Mastro, L; Zambelli, S; Frassoldati, A; Biasi, O; Pusztai, L; Valagussa, P; Viale, G; Gianni, L; Bianchini, G
Distinct neoadjuvant chemotherapy regimens differentially modulate the immune landscape in triple-negative breast cancer, with potential impact on combination with immunotherapy
2025 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Shi, T; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Leveraging public pan-cancer transcriptomic data for immune-oncology: systematic collection and a graphical tool for analysis
2025 Barreca, M; Aranda Cañada, E; Data Gathering Taskforce, I; Sanz Pamplona, R; Callari, M
Development and validation of a gene expression-based Breast Cancer Purity Score
2024 Barreca, M; Dugo, M; Galbardi, B; Győrffy, B; Frassoldati, A; Zambetti, M; Mansutti, M; Zamagni, C; Del Mastro, L; Colleoni, M; Bisagni, G; Gianni, L; Antón-Torres, A; García Sáenz, J; Ciruelos Gil, E; Sevillano, E; Falo, C; Bermejo, B; Volkov, N; Gennadievich, A; Frolova, M; Semiglazov, V; Malter, W; Schumacher, C; Schneeweiss, A; Lück, H; Tesch, H; Behringer, D; Graffunder, G; Sagasser, J; Thill, M; Egle, D; Greil, R; O'Connor, M; Kennedy, J; Morris, P; O'Reilly, S; Kelly, C; Tseng, L; Liu, L; Hou, M; Chen, S; Huang, C; Russo, S; Bianchini, G; Zambelli, S; Gambaro, A; Mariani, G; Bengala, C; Montemurro, F; Valagussa, P; Besozzi, D; Viale, G; Bianchini, G; Callari, M
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
2023 Licata, L; Barreca, M; Galbardi, B; Dugo, M; Viale, G; Gyorffy, B; Karn, T; Pusztai, L; Gianni, L; Callari, M; Bianchini, G
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response
2023 Bosi, C; Bartha, Á; Galbardi, B; Notini, G; Naldini, M; Licata, L; Viale, G; Mariani, M; Pistilli, B; Ali, H; André, F; Piras, M; Callari, M; Barreca, M; Locatelli, A; Viganò, L; Criscitiello, C; Pusztai, L; Curigliano, G; Győrffy, B; Dugo, M; Bianchini, G
Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment
2022 Callari, M; Barreca, M; Dugo, M; Galbardi, B; Vigano, L; Locatelli, A; Licata, L; Viale, G; Valagussa, P; Viale, G; Gianni, L; Bianchini, G
Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial
2022 Callari, M; Huang, C; Egle, D; Bermejo, B; Zamagni, C; Dugo, M; Thill, M; Anton, A; Barreca, M; Russo, S; Ciruelos, E; Greil, R; Zambelli, S; Gyorffy, B; Smart, C; Biasi, O; Valagussa, P; Viale, G; Gianni, L; Bianchini, G